ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
会议论文

Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study

Wang, Xiaojia; Lee, Keun Seok; Zeng, Xiaohua; Sun, Tao; Im, Young-Hyuck; Li, Huiping; Wang, Kun; Li, Huiyan; Zhou, Ping; Bao, Yuanyuan; Jiang, Zefei广东省人民医院; 南方医科大学; 中国医科大学; 重庆大学; 5
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)2023-6-1
5阅读
引用收藏
分享
相关
加载中…
  • Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer
    Zhang, Q.; Wang, J.; Ouyang, Q.; Wang, X.; Lin, D.; Wang, J.; Gan, L.; Ouyang, Z.; Xu, T.; Liu, Y.; Lv, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
  • Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial
    Xu, B.; Yan, M.; Ma, F.; Li, W.; Ouyang, Q.; Tong, Z.; Teng, Y.; Wang, S.; Wang, Y.; Geng, C.; Luo, T.; Zhong, J.; Zhang, Q.; Liu, Q.; Zeng, X.; Sun, T.; Mo, Q.; Dong, F.; Wu, S.; Zhu, X.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.被引 11
  • The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study
    Shao, Z.; Huang, T.; Fan, Z.; Wang, Y.; Yan, X.; Yang, H.; Wang, S.; Pang, D.; Li, H.; Wang, H.; Geng, C.; Huang, L.; Siddiqui, A.; Wang, B.; Xie, B.; Sun, G.; Restuccia, E.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
查看全部 →

会议信息

会议名称
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
会议日期
2023-06-02 至 2023-06-06
论文集名
JOURNAL OF CLINICAL ONCOLOGY
发表日期
2023-06-01
资助标注
BeiGene, Ltd.
收录
ISTP

作者

  • W

    Wang, Xiaojia (第一作者)

  • L

    Lee, Keun Seok

查看全部 11 位作者收起作者
  • Z

    Zeng, Xiaohua

  • S

    Sun, Tao

  • I

    Im, Young-Hyuck

  • L

    Li, Huiping

  • W

    Wang, Kun

  • L

    Li, Huiyan

  • Z

    Zhou, Ping

  • B

    Bao, Yuanyuan

  • J

    Jiang, Zefei

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417